Quiz #2 Material Flashcards

(35 cards)

1
Q

Protein Receptor Signaling Pathways

A
  • Channel-linked receptors
    • Milliseconds
    • Nicotinic, Ach receptors
  • GPCR
    • Seconds
    • Muscarinc, Ach receptors
  • Kinase-linked
    • Minutes
    • Insulin receptors
  • Nuclear receptors
    • Hours
    • Estrogen receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drugs-Receptor Interactions

A
  • Drug-receptor binding is reversible, bimolecular
    • Bimolecular=one drug, one receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Add drug to a beaker with given concentration of receptors:

A
  • Receptors become saturated at equilibrium
  • At equilibrium dissociation and association rates are equal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Law of Mass Action

A
  • K1=association rate constant
  • K2=dissociation rate constant
  • K2/K1=Kd=([D][R])/[DR]
  • Kd=equilibrium dissociation constant; a measure of drug’s affinity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fractional Receptor Occupancy

A
  • Rearrange Law of Mass Action
  • [DR]/[Rt]=[D]/(Kd+[D])
  • Fraction of the receptors bound by drugs depends only on [D] and Kd
  • When the concentration of the drug equals Kd, 50% of receptors will be bound by drug
  • Drug is always in excess so that you’ll always get the same FRACTION that binds
    • Doesn’t matter how many receptors are in the system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Drug-Binding Curve

A
  • Receptors bounds vs. log scale dose
  • Kd=drug concentration to bind 50% of receptors
  • Small Kd, greater affinity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Drug:Receptor Complex and Drug Effect

A
  • Drug effect is proportional to [Drug:Receptor]
  • Max effect when all receptors are bound
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Efficacy vs. Potency

A
  • Emax=max effect of drug=efficacy
  • Potency=EC50=drug that produce 50% of effect
    • Smaller EC50 means a more potent drug
  • Do you prescribe a more potent drug or a more efficacious drug?
    • Depends on magnitude of change that you want (disregarding toxicities)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Classical Theory of Drug Action: “Occupancy Model”

A
  • [D]+[R]→Kd→[DR]—–→Response
  • Assumptions
    • Simple, bimolecular reaction that is reversible
    • Magnitude of response proportional to [drug:receptor]
      • effect=[RD]
    • Max response when all receptor occupied
      • Emax=100% occupancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Affinity vs. Potency

A
  • Affinity
    • Drugs ability to bind receptor
    • Defined by Kd
  • Potency
    • Amount of drug to produce effect
    • Defined by EC50
  • Can conclude that Kd=EC50
    • Drugs with higher affinity are more potent
      • (True in most cases, but sometimes it doesn’t signal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Types of Agonists:

A
  • Full agonist:
    • Produce maximal effect
    • Will always have a higher efficacy than a partial agonist, however WILL NOT always be more potent than a partial agonist
  • Partial agonists
    • Lower efficacy than full agonist
    • Cannot produce max effect even when all receptors are bound
  • Inverse agonists
    • Reduce the low level of constitutive/basal activity observed in the absence of any agonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drug-Binding curve for partial vs. full agonists:

A
  • Both can still bind 100% of receptors (y-axis)
  • Drug with higher affinity will have a lower Kd (curve shifted left)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dose-Response curve for partial vs. full agonists:

A
  • Y-axis is % max response
  • Partial agonist will not reach 100% max response
  • Drug with higher affinity will be shifted left (lower EC50)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Model of Drug-Receptor Action

A
  • Two Receptor Conformations
    • Ri = inactive form that produces no effect when bound by agonist
    • Ra = active form that produces a small effect in absence of bound agonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drug-Receptor Interactions: Partial, Full and Inverse Agonist

A
  • Full agonist
    • much higher affinity for Ra than for Ri
  • Partial agonist
    • somewhat higher affinity for Ra than for Ri
  • Inverse agonist
    • much higher affinity for Ri than for Ra
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why is an inverse agonist not called an antagonist?

A
  • Inverse agonist alone is able to produce an effect
  • An antagonist exerts an effect only int the presence of an agonist
17
Q

Pharmacodynamics

A
  • Study the action of drugs on the body
18
Q

Competitive Antagonist: Active Site Reversible Binding

A
  • Antagonist binding does not activate the receptor
  • Shifts dose-response curve to the right
  • Decreases potency of agonist (Increase EC50)
  • No change in efficacy (Emax)
  • Surmountable: Effects of competitive antagonist can be overcome by increasing agonist concentration
19
Q

Noncompetitive Antagonist: Active Site Irreversible Binding

A
  • Covalent bond
  • Reduces total number of receptors available for agonist binding
  • Shifts the dose-response curve downward
  • Reduces efficacy of agonist
  • No change in potency
  • Insurmountable: Effects of irreversible antagonist cannot be overcome by increasing concentration of agonist
    • # of receptors decreases→have to make more
20
Q

Varenicline (Chantix) Example:

A
  • Partial agonist at nicotinic receptors in the brain
  • Binds to nicotine receptors
  • Effect in brain is less than nicotine because it is a partial agonist
  • Acts like a competitive antagonist against nicotine to outcompete nicotine at the receptor
    • Reduces the max effect of A
  • B is a competitve antagonist agains tthe copetitve antagonist of A. B alone=partial agonist
21
Q

Noncompetitive Allosteric Antagonist

A
  • Binds to receptor at site different from agonist
  • Does not bind to the active site
  • Blocks the responsiveness of the receptor to agonist
    • Prevents binding of agonist to active site of receptor
    • Abolishes activation of the receptor after agonist binds
  • See a decrease in the max response
  • It is A+D in figure below
22
Q

Summary of Receptor Antagonist Action

A
  • Competitive antagonist
    • Decreases potency
    • Binds reversibly to active site of receptor
  • Noncompetitive active site antagonist
    • Decreases efficacy
    • No effect on potency because the affinity for the receptor is the same. 50% of the lower efficacy is the same as 50% of the higher efficacy
    • Binds irreversible to active site of receptor
  • Noncompetitive allosteric antagonist
    • Decreases efficacy
    • Binds reversibly or irreversibly to site other than active site of receptor
23
Q

Physiological Antagonist

A
  • Agonist and antagonist bind two different receptors
  • Activation of the two receptors produces opposing physiological effects
    • Effects that cancel each other out
    • I.e. Elevated glucocorticoid levels can lead to hyperglycemia. Administer insulin as physiological antagonist to reduce blood sugar levels
  • Physiological antagonists bind to a receptor and produce an effect
    • Differ from all other antagonists
24
Q

Chemical Antagonist

A
  • Do not interact with a receptor
  • Interact directly with the drug/agonist
      1. Remove the drug from the system
      1. Prevent the drug from binding to its receptor
  • Gets eliminated or secreted from the body
  • Decreases drug concentration in the body
  • Examples:
    • Protamine sulfate: stably bind to heparin and reverses anti-coagulant effects
  • Dimercaprol: binds to toxic metals which are then excreted in the urine
25
Therapeutic Considerations:
* Patient with bradycardia caused by increased release of acetylcholine from vagus nerve endings * Administer isoproterenol, agonist for beta-adrenergic receptor that increases heart rate (different receptor) * Physiological antagonist * Administer atropine, which binds the active site and block the receptors at which acetylcholine acts to slow heart rate * Competitive antagonist * Could also be irreversible active site antagonist (Noncompetitive antagonist) * Need more information to determine
26
Allosteric Modulators
* Bind to a site on the receptor that is different from the active binding site for the agonist * 1. Alter the affinity of the agonist for the receptor * 2. Alter the level of receptor activation after agonist binding * Increase: Positive allosteric modulator * Decrease: Negative allosteric modulator
27
Allosteric Modulator Action
* Positive Modulator: Affinity * Increases affinity of agonist for receptor * Increases potency * Positive Modulator: Action * Increases level of receptor activation by agonist * Increases efficacy * Negative Modulator: Affinity * Decreases affinity of agonist for receptor * Decreases potency * Negative Modulator: Activation * Decreases level of receptor activation by agonist * Decreases efficacy
28
Allosteric Modulators of GABA Receptor
* GABA binds; Chloride flows; Inhibits neuronal function * Midazolam; GABA affinity is higher * Need less GABA to activate
29
Irreversible Active Site Antagonist
* Decreases max response of agonist * Looks like potency because of spare receptors
30
Spare Receptors Exist When:
Maximal response to a drug can be achieved when less than all the available receptors are bound by drug
31
Spare receptors lower the agonist concentration required to produce a given response
* To activate two receptors: * No spare receptors: [Agonist]=Kd * With spare receptors: [Agonist] are less than Kd *
32
Total receptor concentration for morphine is X and the max response requires X receptors to be bound. Treatment with naltrexone, a morphine receptor antagonist, leads to a 50% increase in total number of receptors. What effects does the increase in receptor concentration have on morphine’s: * Efficacy * Potency * Affinity
* Efficacy: No change * Potency: Increases * Affinity: No change
33
Physiological System with Spare Receptors
* Leydig cells * Adjacent to seminiferous tubules in the testicle * Express receptors for LH * Produce testosterone and other steroid hormones in response to LH * Max hormone production observed with 1% of LHR bound by agonist * LHR is a GPCR that activates AC * Reach amount of cAMP needed for hormone response with only 1% LHR activated * When the number of receptors exceeds the number of effector molecules * 40 GPCR but only 4 G-proteins * Max response needs all 4 G-proteins activation * Only 10% receptor occupancy necessary to produce the max response
34
Why Have Spare Receptors?
* Potential protective effect * Spare receptors bind up extra agonist without producing any additional response * (1) Increase the sensitivity of the system for agonist * (2) Protective effect * (3) Allows for rapid onset and termination of a desired response (such as in neurotransmission) * Obtain desired response at very low concentrations of an agonist that has a relatively low affinity * 1. Spare receptor=sensitivity to low drug concentration * 2. Low affinity=more rapid dissociation and termination of the response * Drug is floating on and off; get a signal turned on at low concentration but then turned off quickly
35
EC50 and Kd relationship when there are spare receptors
* EC50
  • Increases drug potency
  • Spare receptors are present when maximal drug response can be achieved with less than 100% of the receptors bound by drug